普利製藥(300630.SZ):特利加壓素注射液獲得藥品註冊批件
格隆匯9月4日丨普利製藥(300630.SZ)公佈,公司於近日收到國家藥品監督管理局簽發的特利加壓素注射液藥品註冊批件。
特利加壓素注射液最早於2010年9月23日在歐洲獲批上市,上市的國家包括德國、荷蘭、英國、西班牙、意大利等,上市許可持有人為Ferring公司。
近日,公司收到國家藥品監督管理局簽發的新註冊分類3類的藥品註冊批件,同時公司的特利加壓素注射液是國內首個獲批的注射液劑型。這標誌着普利製藥的特利加壓素注射液具備了在中國上市銷售的資格,對公司拓展國內市場帶來積極影響。特利加壓素化學名為三甘氨酰賴氨酸加壓素,是一種人工合成的長效血管加壓素。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.